Search hospitals > Iowa > Bettendorf
University of Iowa Healthcare Cancer Services Quad Cities
Claim this profileBettendorf, Iowa 52722
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
152 reported clinical trials
9 medical researchers
Summary
University of Iowa Healthcare Cancer Services Quad Cities is a medical facility located in Bettendorf, Iowa. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. University of Iowa Healthcare Cancer Services Quad Cities is involved with conducting 152 clinical trials across 189 conditions. There are 9 research doctors associated with this hospital, such as Muhammad Furqan, Yousef Zakharia, MD, Pashtoon Kasi, MS, and Chandrikha Chandrasekharan, MBBS.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Muhammad FurqanUniversity of Iowa Healthcare Cancer Services Quad Cities5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
21 reported clinical trials
36 drugs studied
Yousef Zakharia, MDUniversity of Iowa Hospitals and Clinics2 years of reported clinical research
Studies Cancer
Studies Renal Cell Carcinoma
19 reported clinical trials
45 drugs studied
Pashtoon Kasi, MSUniversity of Iowa/Holden Comprehensive Cancer Center2 years of reported clinical research
Expert in Colorectal Cancer
Studies Adenocarcinoma
19 reported clinical trials
48 drugs studied
Chandrikha Chandrasekharan, MBBSUniversity of Iowa/Holden Comprehensive Cancer Center5 years of reported clinical research
Studies Neuroendocrine Tumors
Studies Tumors
17 reported clinical trials
40 drugs studied
Clinical Trials running at University of Iowa Healthcare Cancer Services Quad Cities
Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Multiple Myeloma
Colorectal Cancer
Small Intestinal Adenocarcinoma
Plasma Cell Neoplasms
Cancer
ALK Gene Rearrangement
Recurrence
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Iowa Healthcare Cancer Services Quad Cities?
University of Iowa Healthcare Cancer Services Quad Cities is a medical facility located in Bettendorf, Iowa. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. University of Iowa Healthcare Cancer Services Quad Cities is involved with conducting 152 clinical trials across 189 conditions. There are 9 research doctors associated with this hospital, such as Muhammad Furqan, Yousef Zakharia, MD, Pashtoon Kasi, MS, and Chandrikha Chandrasekharan, MBBS.